Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II)

BACKGROUND: BAY 81-8973 is a new full-length human recombinant factor VIII product manufactured with technologies to improve consistency in glycosylation and expression to optimize clinical performance. OBJECTIVES: To demonstrate superiority of prophylaxis vs. on-demand therapy with BAY 81-8973 in p...

Descripción completa

Detalles Bibliográficos
Autores principales: Kavakli, K, Yang, R, Rusen, L, Beckmann, H, Tseneklidou-Stoeter, D, Maas Enriquez, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Clinical Haemostasis and Thrombosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671268/
https://www.ncbi.nlm.nih.gov/pubmed/25546368
http://dx.doi.org/10.1111/jth.12828

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671268/
https://www.ncbi.nlm.nih.gov/pubmed/25546368
http://dx.doi.org/10.1111/jth.12828

Ejemplares similares